Oral Solid Dosage

The state-of-the-art Oral Solid Dosage unit is designed as per US FDA standards. The facility incorporates contemporary technological advancements with automated material handling systems and multilevel designs to enable gravity feed between various processing stages. This facility houses a total of five lines with an annual capacity to produce 5 billion tablets on a single shift basis. Our modern OSD facility is already accredited by the regulatory authorities of EU, Australia and the Gulf member states, and the Company is highly focused on entering the regulated markets of US, EU and Australia.

Metered Dose Inhaler

Beximco Pharma was among the first few companies in the world who made the transition away from CFC-based inhalers to the ozone benign HFA based formulations, in compliance with the Montreal Protocol. The Company proactively developed ozone benign HFA based MDIs which require very high level of expertise and sophisticated technology. Beximco Pharma is currently the largest producer of MDIs in Bangladesh, and it produces a popular inhaler brand for a global MNC under a contract manufacturing agreement. The MDI units have been designed with the technical collaboration from Pamasol, Switzerland; which now have an annual production capacity of 20 million canisters.

Ophthalmic

Beximco Pharma’s ophthalmic facility was launched in 2009. Today this facility has been accredited by the regulatory authorities of EU and Australia and the Company has differentiated itself by maintaining global quality standards. There is increasing response from European clients where the demand for generic ophthalmic products is rising due to patent expiration of a number of key products. Currently a good number of ophthalmic products are being manufactured which include products like Xalaprost (Latanoprost), Xalanol (Latanoprost+Timolol), Odycin (Moxifloxacin), Olopan (Olopatadine),etc.

Intravenous Fluid

Our Intravenous (IV) fluid unit is ISO 9001: 2010 certified and was designed in collaboration with Pharmaplan, a sister concern of Fresenius AG of Germany.

Absolute sterile manufacturing conditions are rigorously maintained through a series of fully automated manufacturing procedures including the robotics. The facility utilizes FFS (Form-Fill-Seal) BottlePack® aseptic system of Pharmaplan Germany. Plastic bottles are blow molded, filled with the solution and sealed under sterile conditions, in a single working cycle where there is no environmental exposure or human contact during manufacturing. The whole process is performed in a Class 100 clean room which ensures the highest standards of quality and purity. The facility produces a broad assortment of large volume parenterals (LVPs). As a line extension of this IV unit, the company has installed amino acid line to produce a range of parenteral nutrition products such as Nutrimin D (7% Composite Amino Acid IV Infusion with 10% Glucose and Electrolytes), Dexaqua (Dextrose 5%), Dexoride 500 (Sodium Chloride 0.9% and Dextrose 5%) etc.

Liquid and Semisolid

Beximco Pharma has a broad range of liquid formulations like syrups etc. and semisolid dosage forms including creams and ointments. At present the capacity of liquid dosage facility is 37 million units per annum and the Company has taken up expansion program along with further upgradation of the existing unit to meet the growing demand. The Company currently has the capacity to produce 6 million units of creams and ointments and 10 million units of suppositories.

Prefilled Syringe

Prefilled syringes (PFS) provide both convenience and accuracy to self-administered drugs. With their ease of use and improved safety features, PFS has become one of most widely used drug delivery systems today.

Beximco Pharma launched PFS range with enoxaparin sodium, a low molecular weight heparin, which is widely used in cardiac emergency. The Company plans to add a few more high value products to its PFS portfolio shortly. The high precision PFS line employs sophisticated technology and the entire filling operation is done under laminar flow in a Class 100 environment to provide absolute sterile conditions. (Pfs)

Dry Powder Inhaler

Dry powder inhaler (DPI) is a device that delivers medication to the lungs in the form of a dry powder. DPIs do not require the timing and coordination that are necessary with metered-dose inhaler and they do not contain any propellants. Beximco Pharma offers dry powder inhaler in innovative patient-friendly packaging. Instead of bottle pack, we provide alu-alu blister pack which protects medicine from moisture. HPMC capsule shell ensures maximum protection against moisture. And our unique and simple Bexihaler® device, imported from Europe, and consisting of 8 pins, ensures optimum dose delivery. Currently the facility has the capacity to produce 36 million units of DPI every year.

Lyophilized Injectable

Lyophilization is a complex and facility-intensive operation where Beximco has demonstrated its skill through quick and successful adoption of this relatively newer technology. The company within a short span of time emerges as an important player in this area with its range of PPIs and other formulations.